NCT07426068 is a EARLY_PHASE1 clinical trial of Autologous differentiated myocyte transplantation in Metabolic Disease, sponsored by National Clinical Research Center for Orthopedics, Sports Medicine and Rehabilitation, China.

What drugs are being tested in NCT07426068?

Interventions in NCT07426068: Autologous differentiated myocyte transplantation.

What condition does NCT07426068 study?

NCT07426068 studies Metabolic Disease, Amyotrophy.

Is NCT07426068 still recruiting?

NCT07426068 is currently not yet recruiting. Last updated 23 February 2026.

Last reviewed 2026-02-23 · How we verify

NCT07426068

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Safety Evaluation and Preliminary Efficacy Study of Subcutaneous Myografts Transplantation

Not yet recruiting EARLY_PHASE1 Last updated 23 February 2026

What this trial tests

EARLY_PHASE1 trial testing Autologous differentiated myocyte transplantation in Metabolic Disease in 6 participants. Not yet recruiting.

Timeline

1 July 2026

Primary endpoint
1 February 2028

1 February 2028

Quick facts

Lead sponsor	National Clinical Research Center for Orthopedics, Sports Medicine and Rehabilitation, China
Phase	EARLY_PHASE1
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	6
Start date	1 July 2026
Primary completion	1 February 2028
Estimated completion	1 February 2028
Sites	2 locations across China

Drugs / interventions tested

Autologous differentiated myocyte transplantation — full drug profile →

Conditions studied

Metabolic Disease — all drugs for Metabolic Disease →
Amyotrophy — all drugs for Amyotrophy →

Sponsor

National Clinical Research Center for Orthopedics, Sports Medicine and Rehabilitation, China

Who can join

Adults 18 to 80, any sex, with Metabolic Disease or Amyotrophy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to apply autologous differentiated myocyte subcutaneous transplantation in patients with muscle atrophy to explore its safety, feasibility, and efficacy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Metabolic Disease

Currently open trials in the same condition.

NCT06575426 — A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes M · Phase 1, PHASE2 · recruiting
NCT06938386 — Pilot Haskap Metabolite Timing Project · NA · active not recruiting
NCT06954298 — Molecular Landscape of Complex Lifestyle Modification · NA · active not recruiting
NCT06717581 — Variation in Drug Interactions in People With HIV (PLWH) Aged 60 Years and Older. · recruiting
NCT06529965 — Evaluating a Digital Intervention for Alleviating Diabetes-specific Emotional Distress in Adults Living With T2DM · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07426068 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Clinical Research Center for Orthopedics, Sports Medicine and Rehabilitation, China
Last refreshed: 23 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07426068.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing